Stockscreener 앱 받기
183.82
1.40%
2.36
전일 마감가:
$181.46
열려 있는:
$183.48
하루 거래량:
207.62K
Relative Volume:
0.13
시가총액:
$26.99B
수익:
$9.53B
순이익/손실:
$1.29B
주가수익비율:
20.88
EPS:
8.8057
순현금흐름:
$1.97B
1주 성능:
+0.40%
1개월 성능:
-6.29%
6개월 성능:
+32.08%
1년 성능:
+30.59%
1일 변동 폭
$183.00
$185.00
1주일 범위
$180.47
$186.52
52주 변동 폭
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
183.90 | 26.63B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
917.37 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.13 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.05 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
115.59 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
184.18 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2025-11-06 | 업그레이드 | Stifel | Hold → Buy |
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen Inc. Stock Stifel CNS Forum: $190 Target Price Driven by Tau Pipeline Pivot - TIKR.com
Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential - simplywall.st
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 - ACN Newswire
Swiss Life Asset Management Ltd Sells 21,970 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MSN
How Class Action Risks and Lupus Drug Advances Could Reframe Biogen's (BIIB) Innovation Narrative - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Lecanemab shows 67% patient retention at 24 months in US study - Investing.com
Why Biogen Inc. (BIIB) is a top value stock for the long term - MSN
Biogen Inc. stock gains momentum from pipeline advances and analyst upgrades amid biotech recovery - AD HOC NEWS
BIIB: High Persistence of Lecanemab Treatment in Real-World Anal - GuruFocus
Biogen unveils real-world data on early Alzheimer treatment persistence in U.S. - Traders Union
Eisai and Biogen Report High Treatment Persistence for Lecanemab in Real-World Alzheimer's Patients - Quiver Quantitative
Eli Lilly, Biogen/Eisai win UK review for use of Alzheimer’s drugs in NHS - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Eli Lilly (LLY) and Biogen (BIIB) Alzheimer's Drug Review by UK Watchdog - GuruFocus
U.K. to review use of Alzheimer’s drugs in NHS (LLY:NYSE) - Seeking Alpha
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
England to Review Rejection of Alzheimer’s Drugs for NHS - Bloomberg.com
PSA Biogas Upgrading Market Is Going to Boom | Biogen • Xebec Adsorption Inc. • Aqualia - openPR.com
Farmers Trust Co. Increases Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by AIA Group Ltd - MarketBeat
Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline - TipRanks
Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study - TipRanks
Biogen to present litifilimab data for cutaneous lupus at AAD - Investing.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - marketscreener.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - GlobeNewswire Inc.
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting - Biogen
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Insight Wealth Strategies LLC Buys Shares of 28,960 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans - Yahoo Finance
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's why Biogen Inc. (BIIB) is a strong momentum stock - MSN
Biogen at Stifel Forum: Strategic Insights on Alzheimer’s and Neuromuscular Advances - Investing.com
BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials - TradingView
Biogen Inc. (NASDAQ: BIIB) Q4 2025 earnings call transcript - MSN
HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII - GuruFocus
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says - MarketBeat
Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns - simplywall.st
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus - Yahoo Finance
Dow Update: Is Biogen Inc showing insider buying2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Gotham Asset Management Boosts Biogen Stake by 65% - National Today
Gotham Asset Management LLC Has $37.89 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Stock Holdings Boosted by Brevan Howard - National Today
Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
Behavioral Patterns of BIIB and Institutional Flows - Stock Traders Daily
Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB - MarketBeat
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Cinctive Capital Management LP Raises Stake in Biogen Inc. $BIIB - MarketBeat
What makes Biogen (BIIB) an attractive long-term holding? - MSN
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.37%
자본화:
|
볼륨(24시간):